Civica

Nomi Health Launches Charitable Foundation to Expand Access to Affordable, High-Quality Healthcare

Retrieved on: 
Thursday, February 23, 2023
Software, General Health, Philanthropy, Training, Technology, Other Education, Continuing, Health Technology, Health Insurance, Education, Foundation, Other Philanthropy, Health, Transport, Insulin, RIP Medical Debt, Special Olympics, Housing, University, Prison, Nomi, Council, Organization, Voice for Children and Families, Miami Dade College, Encircle, Patient, Health literacy, Moses Austin, Social, Face, Goodwill Industries, Practitioner, Student, COVID-19, Physician, Civica, Pharmaceutical industry, Hospital, Nursing, Engineering, Science, STEAM

Nomi Health , a direct healthcare company, has announced the creation of the Nomi Health Charitable Foundation to advance the company’s efforts to expand access to high-quality affordable healthcare across the United States.

Key Points: 
  • Nomi Health , a direct healthcare company, has announced the creation of the Nomi Health Charitable Foundation to advance the company’s efforts to expand access to high-quality affordable healthcare across the United States.
  • “Our mission at Nomi Health is to rewire the U.S. healthcare system to run at half the cost while increasing access for all.
  • That’s why we’re launching the Nomi Health Charitable Foundation to formalize our years-long commitment to take on the deeply rooted inequalities in our broken healthcare system and to uplift those who have been left behind.”
    Through philanthropic investments and partnerships, the Nomi Health Charitable Foundation will focus on four key areas of impact:
    Healthcare Equity: Nomi Health focuses on addressing health disparities by increasing access to affordable, high-quality care – including mental healthcare.
  • The Nomi Health Charitable Foundation is launching a new signature program – The Frontline Futures Program – to support students and young professionals pursuing careers in healthcare.

Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative

Retrieved on: 
Tuesday, January 31, 2023
Biotechnology, Diabetes, Other Health, Health, Pharmaceutical, FDA, Insulin lispro, Insulin, Pharmaceutical industry in Switzerland, Pharmaceutical industry, Civica

Civica, Inc. (Civica, Civica Rx) today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins.

Key Points: 
  • Civica, Inc. (Civica, Civica Rx) today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins.
  • To ensure redundancy of supply, Ypsomed will provide injector dosing pens from their two manufacturing facilities in Switzerland and Germany.
  • “As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,” said Ned McCoy, President and Chief Executive Officer of Civica.
  • Contingent on FDA approval, Civica anticipates that its insulins will be available for purchase beginning as soon as 2024.

AmerisourceBergen Kicks Off Strategic Relationship with Civica

Retrieved on: 
Monday, January 23, 2023
Medical Supplies, Manufacturing, Managed Care, Health, Other Transport, General Health, Pharmaceutical, Transport, Other Manufacturing, Hospitals, Logistics, Supply Chain Management, Federation, AmerisourceBergen, Multimedia, COVID-19, Patient, Partnership, Pharmaceutical industry, Nursing, Civica

Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members.

Key Points: 
  • Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members.
  • Through its distribution network, AmerisourceBergen will work to ensure that Civica’s crucial products reach its members across the country efficiently, reliably, and securely.
  • View the full release here: https://www.businesswire.com/news/home/20230123005078/en/
    “We are thrilled to have AmerisourceBergen as our like-minded distribution and supply chain partner as we continue to grow our hospital network,” said Ned McCoy, President and CEO of Civica.
  • More than 1,500 pharmaceutical manufacturers and tens of thousands of healthcare providers rely on AmerisourceBergen every day to deliver critical medicines and treatments.

Emerging Life Sciences Market Shapes the Region

Retrieved on: 
Monday, November 21, 2022
Quality of life, Workforce, Commonwealth, Health, Education, Insulin, DPR, Risk, Civica, Market, DPR Construction, Corridor, VCU, Tenant, Fine chemical

RICHMOND, Va., Nov. 21, 2022 /PRNewswire/ -- In a panel focused on current advanced manufacturing and life science developments hosted by BISNOW, DPR Construction's Raj Vora offered his thoughts on Richmond's rich business climate. Vora shared his insights on how Richmond compared to the larger biotechnology hubs along Maryland's I-270 Corridor and North Carolina's Raleigh-Durham region.

Key Points: 
  • Vora shared his insights on how Richmond compared to the larger biotechnology hubs along Maryland's I-270 Corridor and North Carolina's Raleigh-Durham region.
  • "The educated workforce and quality of life in the region, amplified by Richmond's proximity to research facilities, has attracted newcomers and life sciences startups," said Vora.
  • The key takeaway should be cautious optimism with a positive outlook on the life sciences industry's ability to take hold in Richmond."
  • DPR Construction is a forward-thinking, self-performing general contractor and construction manager specializing in technically complex and sustainable projects for the advanced technology, life sciences, healthcare, higher education and commercial markets.

Richmond-Petersburg Region is a Winner of the National Build Back Better Regional Challenge

Retrieved on: 
Friday, September 2, 2022
Commerce, COVID-19, U.S. Department of Defense Strategy for Operating in Cyberspace, Senator Warner, CEO, Technology, Research, Community college, J. Sargeant Reynolds Community College, City, Organization, Commonwealth Center for Children and Adolescents, Warner, Alliance, Workforce, College, U.S. Department of Commerce Office of Security, Student, Poor Creek, Economic development, BrightPoint, Ecosystem, Industry, VA, Reynolds, General assembly, Innovation Center station, VCU, Veteran, R, Commonwealth, Virginia State University, Civica, EDA, Water, Small business, Economy, Growth, Engineering education, Private sector, University, Maharashtra Legislative Assembly, F.H.W. Briggman House, MSA, Build Back Better Plan, Member of Congress, Knowledge, Airline, Renewable energy, Engineering, Greater Richmond Region

The coalition is one of only 21 coalitions to receive funding from the Build Back Better Regional Challenge.

Key Points: 
  • The coalition is one of only 21 coalitions to receive funding from the Build Back Better Regional Challenge.
  • Coalition members will leverage the Build Back Better Regional Challenge funding for six construction and programmatic projects.
  • Funding from the Build Back Better Regional Challenge will help the region create a secure supply of essential medicines for the U.S., re-shore manufacturing by tapping into new technologies, and reduce the cost and increase access to quality medicines for Americans.
  • "We thank the General Assembly and governor, GO Virginia and VEDP for strong and growing support for this emerging regional cluster.

Lumicera Health Services Now Offering The First Landmark Drug From CivicaScript™

Retrieved on: 
Thursday, August 11, 2022
Managed Care, Pharmaceutical, Health, Oncology, SSM Health, Blue Cross Blue Shield Association, Prostate cancer, Pharmacy, PBM, Prescription, Welfare, Health, Patient, Twitter, BCBS, Civica, Partnership, Tablet, Philosophy, News, Health Care Service Corporation, Anthem, LinkedIn, Prednisone, Costco, Pharmaceutical industry, Health insurance, Navitus Bay wind farm, Lumicera

Lumicera Health Services, a specialty pharmacy wholly owned by Navitus Health Solutions, announced today that it will be offering abiraterone acetate 250 mg tablets the first landmark generic drug made available by CivicaScript.

Key Points: 
  • Lumicera Health Services, a specialty pharmacy wholly owned by Navitus Health Solutions, announced today that it will be offering abiraterone acetate 250 mg tablets the first landmark generic drug made available by CivicaScript.
  • The partnership between Lumicera and CivicaScript provides an opportunity to uniquely benefit payors and patients by furthering the shared commitment to transparency and drug affordability.
  • This drug launch comes on the heels of Navitus Health Solutions announcing it has joined CivicaScript as a founding member.
  • Navitus Health Solutions, owned by SSM Health and Costco Wholesale Corporation, is a disruptive industry alternative to traditional pharmacy benefit manager (PBM) models.

ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development

Retrieved on: 
Tuesday, August 9, 2022
Multimedia, CAR, Industry, CEO, Division, CFO, Asian Institute of Management, Technology, Growth, Abbott, Cancer, UCLA, Leadership, MBM, Wharton School of the University of Pennsylvania, Johnson & Johnson Vision, Patient, Bayer, Civica, Health, Partnership, VP, Series, M&A, University, BD (company), University of California, Toxic shock syndrome, Immune system, Korea University of Science and Technology, Management

WEST HILLS, Calif., Aug. 9, 2022 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Vikram Lamba, M.B.M. as chief financial officer (CFO) and head of business development. Mr. Lamba replaces Anat Nursella, who served as CFO at ImmPACT Bio since late 2020.

Key Points: 
  • WEST HILLS, Calif., Aug. 9, 2022 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Vikram Lamba, M.B.M.
  • as chief financial officer (CFO) and head of business development.
  • Mr. Lamba replaces Anat Nursella, who served as CFO at ImmPACT Bio since late 2020.
  • "It is exciting to join ImmPACT Bio at its current stage of successful product development and help scale-up and deliver the pipeline of next-generation CAR T-cell therapies," said Mr. Lamba.

CivicaScript™ Announces Launch of its First Product, Creating Significant Patient Savings

Retrieved on: 
Wednesday, August 3, 2022
Oncology, Professional Services, Health, Insurance, Managed Care, Pharmaceutical, Biotechnology, Pharmacy, Blue Cross, Drug, Prednisone, Health, Blue Shield, Face, PBM, Tablet, Partnership, Patient, Insulin lispro, Insurance, Blue Cross Blue Shield Association, Intermountain Healthcare, Prostate cancer, Sale, Welfare, Insulin aspart, Health Care Service Corporation, CEO, Medication, BCBS, Civica, FDA, Medicare, Prescription, Insulin, Medicare Part D, Dietary supplement, Health insurance, Pharmaceutical industry, Insulin glargine

Starting today, CivicaScript will offer abiraterone 250 mg for sale to pharmacies for $160 per bottle of 120 tablets typically a months supply.

Key Points: 
  • Starting today, CivicaScript will offer abiraterone 250 mg for sale to pharmacies for $160 per bottle of 120 tablets typically a months supply.
  • Abiraterone was chosen by CivicaScriptmembers as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product.
  • This is a proud day for CivicaScript as we advance our mission to make generic medicines affordable and available to everyone, said CivicaScript President Gina Guinasso.
  • CivicaScript then works with like-minded payors, PBMs and pharmacies across the country who pass along the cost savings to their customers.

Navitus Health Solutions Joins CivicaScriptTM to Further Availability of Lower-Cost Generic Medications

Retrieved on: 
Wednesday, July 13, 2022
Professional Services, Health, Insurance, Other Health, Managed Care, General Health, Pharmaceutical, SSM Health, Philosophy, Pharmacy, Health, Costco, Multimedia, BCBS, Prescription, PBM, News, LinkedIn, Welfare, Organization, Patient, CEO, Blue Cross Blue Shield Association, Civica, Association for Accessible Medicines, Health Care Service Corporation, TM, Twitter, Association, Anthem, Partnership, Pharmaceutical industry, Health insurance, Navitus Bay wind farm

This new partnership will enable greater access and distribution of lower-cost medications to consumers, including the 8.7 million members Navitus is proud to serve.

Key Points: 
  • This new partnership will enable greater access and distribution of lower-cost medications to consumers, including the 8.7 million members Navitus is proud to serve.
  • CivicaScript was created in 2020 to bring affordable versions of common but high-priced generic medicines to market.
  • Navitus Health Solutions, owned by SSM Health and Costco Wholesale Corporation, is a disruptive industry alternative to traditional pharmacy benefit manager (PBM) models.
  • By returning 100% of rebates and discounts received and deploying a lowest-net-cost philosophy, Navitus helps reduce costs and improve member health.

Nomi Health Contributes $5 Million to Nonprofit Civica to Address Crisis of Skyrocketing Insulin Costs for Americans

Retrieved on: 
Thursday, June 16, 2022
Biotechnology, Practice Management, Professional Services, Managed Care, Diabetes, Health, Philanthropy, General Health, Pharmaceutical, Environmental, Social and Governance (ESG), Fund Raising, Public health, FDA, COVID-19, Nomi, Public sector, American Diabetes Association, CEO, Insulin, Prediabetes, Program, Open Insulin Project, Health, Conditional sentence, Prevalence, Diabetes, Pharmaceutical industry, Artemis, Civica

“The insulin crisis is not one of supply. It is a crisis of inflated costs driven by a small, yet unchecked, monopoly of pharmaceutical giants -- and it is 100 percent avoidable,” said Mark Newman, CEO and co-founder of Nomi Health. “Price gouging has no place in public health. Americans should not have to choose between insulin and groceries in this day and age. We will continue to identify opportunities for our employer and public sector partners to bend the cost curve in healthcare through our insights-to-action solutions like Artemis. The work Civica is doing to expand access to these life-saving drugs demands urgent attention and action. In contributing to Civica, we at Nomi Health continue to pursue our mission to deliver easy access to low-cost healthcare for all Americans.”

Key Points: 
  • For the approximately 10 million Americans who rely on insulin to save their lives, the cost of insulin has skyrocketed, even despite declines in costs for companies that produce it.
  • In contributing to Civica, we at Nomi Health continue to pursue our mission to deliver easy access to low-cost healthcare for all Americans.
  • Through the support of partners such as Nomi Health, Civica is co-developing and manufacturing the drug, completing clinical trials and filing necessary applications for FDA approval.
  • We thank Nomi Health for joining Civicas affordable insulin initiative, said Ned McCoy, President and Chief Executive Officer of Civica.